Cargando…
SUN-525 Burosumab Experience In A UK Adolescent Population
Objectives X-linked hypophosphatemia (XLH) is a rare inherited form of osteomalacia characterised by low blood phosphate levels which lead to inadequate mineralization of bone:rickets leading in turn to a spectrum of skeletal abnormalities, physical impairment, weakness, and pain. Burosumab is an an...
Autores principales: | Dharmaraj, Poonam, Burren, Christine, Cheung, Moira, Padidela, Raja, Mughal, Zulf, Shaw, Nick, Saraff, Vrinda, Nadar, Ruchi, Randell, Tabitha, Mushtaq, Talat, Ramakrishnan, Renuka, Sennipathan, Senthil, Sakka, Sophia, Bath, Louise, Elleri, Daniela, Davies, Justin, Tucker, Ian, Arundel, Paul, Gilbey-Cross, Robyn, Tothill, Alexander, Connor, Paul, Mathieson, Leigh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553270/ http://dx.doi.org/10.1210/js.2019-SUN-525 |
Ejemplares similares
-
SUN-524 Burosumab Initiation In A UK XLH Cohort: Real-World Use Resonates With Research Evidence
por: Dharmaraj, Poonam, et al.
Publicado: (2019) -
Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British paediatric and adolescent bone group recommendations
por: Padidela, Raja, et al.
Publicado: (2020) -
SUN-523 XLH Outcome Data from One Centre Experience with Burosumab
por: Cheung, Moira, et al.
Publicado: (2019) -
Healthcare resource utilization in the management of hypophosphatasia in three patients displaying a spectrum of manifestations
por: Daniel, Anjali B., et al.
Publicado: (2018) -
Burosumab treatment in a child with cutaneous skeletal hypophosphatemia syndrome: A case report
por: Khadora, Manal, et al.
Publicado: (2021)